Grail was founded in 2015 by Richard (Rick) Klausner, MD and Jeff Huber. The company filed its S-1 registration document with the SEC in September 2020 in advance of a planned Initial Public Offering. Subsequently in the same month, Illumia announced in a press release it had reached a definitive agreement to acquire Grail for $8 billion.

Grail is the developer of a pan-cancer screening test designed to detect cancer early. The company has raised approximately $2 billion in Venture Capital funding from investors including ARCH Venture Partners, Bezos Expeditions, Biomatics Capital, GV, Illumina, Foresite Capital Management, McKesson Ventures, Tencent, Amino Capital, Baillie Gifford, Decheng Capital, Dentsu Ventures, 6 Dimensions Capital, and Blue Pool Capital. Per company press releases, Grail last raised $390 million in May 2020 at a post-money valuation of $3.85 billion.

Register for Details

For more details on financing and valuation for Grail, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Grail's ticker symbol?

Grail does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

What is Grail's stock price?

The stock price for Grail will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Who are Grail's major investors?

Sequoia Capital China
Canada Pension Plan Investment Board
Illumina
SV Angel
PSP Investments
Hillhouse Capital Group
HuangPu River Capital

Grail Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
5/6/2020 Series D $4.26B $XXX.XX $XXX.XX
5/21/2018 Series C $3.2B $XXX.XX $XXX.XX
11/22/2017 Series B $2.35B $XXX.XX $XXX.XX
1/8/2016 Series A $212.5MM $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about Grail

What is Grail funding to date?

Grail has raised $2.02B with the following series:
$212.5MM for Series A, $2.35B for Series B, $3.2B for Series C, $4.26B for Series D

When was Grail founded?

Grail was founded in 2016.

Can you invest in Grail?

Grail is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Can you sell Grail share pre-IPO?

If you own Grail pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Is Grail a publicly traded company?

Grail is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Other companies like Grail in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$298.33MM
Sector
Last Round Est. Valuation
$1.08B
Sector
 
 
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$1.59B